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ABSTRACT 
Objectives: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of 
bisphosphonates (BP). Although the risk of ONJ increases with increasing duration of BP 
treatment, there are currently no reliable estimates of the ONJ time to onset (TTO). The 
objective of this study was to estimate the TTO and associated risk factors in BP-treated 
patients. 
Subjects and methods: Retrospective analysis of data from 22 secondary care centres in 7 
countries relevant to 349 patients who developed BP-related ONJ between 2004 and 2012. 
Results: The median (95%CI) TTO was 6.0 years in patients treated with alendronate (n = 88) 
and 2.2 years in those treated with zoledronate (n = 218). Multivariable Cox regression showed 
that dentoalveolar surgery was inversely associated, and the use of antiangiogenics directly 
associated, with the TTO in cancer patients treated with zoledronate.  
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Conclusions: The incidence of ONJ increases with the duration of BP therapy, with notable 
differences observed with respect to BP type and potency, route of administration and 
underlying disease. When data are stratified by BP type, a time of 6.0 and 2.2 years of oral 
alendronate of intravenous zoledronate therapy, respectively, is required for 50% of patients to 
develop ONJ. After stratification by disease, a time of 5.3 and 2.2 years of BP therapy is required 
for 50% of patients with osteoporosis and cancer, respectively, to develop ONJ. These findings 
have significant implications for the design of future clinical studies and the development of risk 
reduction strategies aimed at either assessing or modulating the risk of ONJ associated with BP. 
 
INTRODUCTION 
Osteonecrosis of the jaw (ONJ) is a serious adverse effect of therapy with bisphosphonates (BP) 
and other anti-resorptive agents (Ruggiero et al, 2009; Sivolella et al, 2013). Affected 
individuals often present with areas of necrotic ischemic jawbone exposed through fenestration 
of the oral mucosa or facial skin (Filleul et al, 2010), while approximately one in four patients 
present with necrotic jawbone covered by intact mucosa (non-exposed variant) (Fedele et al, 
2010). Other manifestations include pain, secondary infection, tooth loss, fistula formation, 
pathological fractures, sinusitis, and oro-antral communication (Filleul et al, 2010). It has been 
estimated that ONJ develops in up to 7% of cancer patients using intravenous BP and in 
approximately 0.12% of osteoporosis patients taking oral BP (Kühl et al, 2012). 
 
The pathogenic mechanisms of, and the risk factors for, ONJ are still controversial (Landesberg 
et al, 2011). For instance, several studies have reported that the risk of ONJ is greater in patients 
who have undergone surgical procedures to the jaw bones (e.g. dental extraction)(Campisi et al, 
2014). However, it is also known that many ONJ cases, possibly up to 30-40%, are not triggered 
by surgical interventions (Filleul et al, 2010). Less controversial is the association between the 
incidence of ONJ and the cumulative dose and duration of BP treatment (Thumbigere-Math et al, 
2012; Fleisher et al, 2013), in keeping with type C adverse drug reactions (Edwards and 
Aronson, 2000). Indeed, the incidence of ONJ is low during the first few years of BP treatment 
and increases substantially thereafter (Barasch et al, 2011). However, it is important to note 
that there is a great variability and inconsistency in the time to ONJ (TTO) reported in the 
literature, possibly because of different study designs and diagnostic criteria, and generally low 
sample sizes (Bamias et al, 2005; Pozzi et al, 2007; Mavrokokki et al, 2007; Boonyapakorn et al, 
2008; Vahtsevanos et al, 2009; Saia et al, 2010; Hasegawa et al, 2012; Watters et al, 2013). 
 
A precise estimate of TTO is important for the design of clinical trials. Trials where follow-up is 
too short would in fact miss most incident cases and provide flawed estimates of ONJ incidence 
and its risk factors. A precise estimate of TTO is also important for developing risk reduction 
strategies (e.g. BP dosage reduction or cessation) and surveillance programs (Fedele et al, 
2009). In order to obtain a more precise estimate of TTO, we have studied the clinical data 
collected in GENVABO, a multicentre cross-sectional study aimed at identifying genetic variants 
predisposing to BP-related ONJ.  
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METHODS 
Study design 
We performed a retrospective secondary analysis of data belonging to a cohort of ONJ patients 
enrolled into the GENVABO (GENetic VAriants as Biomarkers of jaw Osteonecrosis associated 
with bisphosphonates) study, a genome-wide association study with the primary aim of 
identifying genetic variants that predispose to ONJ. The present report follows the STROBE 
recommendations (von Elm et al, 2008). 
 
Setting and inclusion criteria 
GENVABO study was designed by Investigators at the University College London and included a 
total of twenty-two international clinical centres with an interest in the diagnosis and 
management of ONJ. The Ethics Committees of the coordinating centre (Central London REC 4, 
reference 08/H0715/69) and participating sites approved the study and all patients gave their 
written informed consent to participate. Patients referred to the participating centres between 
January 2004 and June 2012 were eligible for GENVABO if they had: 1) ONJ diagnosed as per 
AAOMS criteria (Ruggiero et al, 2009) (Ruggiero et al, 2014); and 2) non-exposed ONJ defined 
as reported by Fedele et al. and other authors (Junquera and Gallego, 2008; Fedele et al, 2010; 
Patel et al, 2011). ONJ was diagnosed and adjudicated in all cases by local multidisciplinary 
teams of specialists in Oral Medicine, Oral and Maxillofacial Surgery, Oncology, Haematology, 
Rheumatology and Radiology. 
 
Data collection  
Clinical charts of consecutive ONJ patients recruited into the GENVABO study between January 
2004 and June 2012 were reviewed and the data of interest were collected between October 
2008 and June 2012. Such data were extracted by local investigators and entered into a 
standardized case report form. All data were inputted into a definitive database using a double 
entry process performed by two different investigators. The data extracted for the present 
analysis included: 1) age, gender and race; 2) details of BP therapy including BP type, date of 
start and length of therapy, and indication for BP use; 3) details of ONJ including date of 
diagnosis, site and type; 4) dental history including history of dentoalveolar surgery and use of 
dentures preceding ONJ diagnosis; 5) medical history including type 2 diabetes mellitus (T2DM) 
and use of corticosteroids and antiangiogenics; 6) smoking history; and 7) recruiting centre and 
relevant country. For patients who had been treated with more than one type of BP, the BP used 
for the longest time was used for the present analysis. The dataset was reviewed by a central 
study panel and underwent data cleaning and verification according to standard procedures. 
Stata 14.1 (Stata Corp., College Station, TX, US) programs were written to ensure the 
reproducibility of data management and data cleaning. 
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Study objectives 
The main aim of GENVABO is to identify genetic variants associated with the risk of developing 
ONJ. The primary objective of the present secondary analysis was to estimate TTO in patients 
with BP-related ONJ. TTO was defined as the number of years elapsed between the initiation of 
BP therapy and the diagnosis of ONJ as outlined above.  We did not attempt to differentiate the 
time to diagnosis from the time to development/onset, as the early symptoms of ONJ can be 
non-specific and they are difficult to assess retrospectively. We also calculated the cumulative 
incidence of ONJ and evaluated the association of TTO with potential risk factors (Thumbigere-
Math et al, 2012; Hasegawa et al, 2012; Fleisher et al, 2013). 
 
Statistical analysis 
The point estimates and the 95% confidence interval of TTO were calculated using the Kaplan-
Meier estimator (Hosmer et al, 2011). Kaplan-Meier curves for TTO were stratified by disease 
(metastatic breast cancer vs. multiple myeloma vs. metastatic prostate cancer vs. other cancers 
vs. osteoporosis), cancer (yes vs. no) and BP (alendronate vs. ibandronate vs. pamidronate vs. 
zoledronate). Multivariable Cox regression was used to test whether TTO was associated with 
gender (discrete, male vs. female), age (continuous, decade), dentoalveolar surgery (discrete, 
yes vs. no), T2DM (discrete, yes vs. no), use of steroids (discrete, yes vs. no) and use of 
antiangiogenics (discrete, yes vs. no) in cancer patients (Model 1) and in non-cancer patients 
(Model 2) (Hosmer et al, 2011). Cluster confidence intervals were calculated using the study 
country as cluster. The proportional hazard assumption made by Cox regression was checked 
using Schoenfeld residuals (Hosmer et al, 2011). Multivariable fractional polynomials were used 
to test whether the multivariable relationship of TTO with age was linear (Royston and 
Sauerbrei, 2008). Statistical analysis was performed using Stata version 14.1. 
 
RESULTS 
Details of the cohort 
Clinical notes of 384 consecutive patients with BP-related ONJ recruited into GENVABO study 
were available for analysis. Missing or conflicting data were identified for 35 (9%) patients, who 
were excluded from further analysis. The majority of the 349 analysed patients (Table 1) were 
of Caucasian origin (93%); 85% were aged ≥ 60 years and 71% were females. The majority (n = 
318; 91%) of the participants had exposed ONJ. The most common indications for ONJ 
treatment were osteoporosis (OP, 32%), multiple myeloma (MM, 27%), metastatic breast 
cancer (MBC, 24%), and metastatic prostate cancer (MPC, 10%). Zoledronate (ZOL, 63%) and 
alendronate (ALE, 25%) were the two most commonly employed BP, followed by pamidronate 
(PAM, 5%), ibandronate (IBA, 4%) and risedronate (RIS, 3%). Concomitant corticosteroids and 
antiangiogenics (bevacizumab, sunitinib, thalidomide, lenalidomide, bortezomib) were used in 
22% and 14% of patients respectively. Dentoalveolar surgery preceding ONJ development was 
reported by 53% of patients, tobacco smoking by 21% and T2DM by 10%. 
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Time to ONJ onset 
In the whole cohort (n = 349), the 50th (95%CI) percentile of TTO was 3.2 (2.8 to 3.7) years, the 
25th percentile 1.7 (1.4 to 1.9) years, and the 75th percentile 5.8 (5.2 to 6.2) years. The minimum 
and maximum TTO were 0.1 and 19.9 years, respectively.  
Table 1 shows the median TTO after stratification on several variables including disease and BP 
type. In brief, when stratified by BP type, the median (50th percentile) TTO was 6.0 (5.3 to 6.4) 
years for ALE and 2.2 (2.1 to 2.6) for ZOL. When stratified by disease, the median TTO was 5.3 
(4.4 to 6.1) years for OP, 3.1 (2.2 to 3.6) for MBC and 2.3 (2.1 to 3.0) for MM. The median TTO 
was 2.2 (2.1 to 2.8) years for all cancer patients (n = 237).  
Figures 1A, 1B and 1C present the Kaplan-Meier plots of the cumulative incidence of ONJ in 
patients stratified by disease, cancer and BP type. Figure 1A shows that ONJ developed faster in 
patients with cancer than in those with osteoporosis. Among patients with different cancer 
types, development was most rapid in those with MPC, followed by OC, MM and MBC (Figure 
1C). Figure 1B shows that ONJ developed faster in patients treated with ZOL, RIS and IBA than 
in those treated with PAM and ALE.  
Table 2 shows the multivariable Cox regression models used to evaluate the association 
between TTO and potential predictors in cancer and non-cancer patients. Model 1 refers to 
cancer patients taking ZOL (212 out of 237 patients with cancer, 89%) while Model 2 refers to 
non-cancer patients taking ALE (84 out of 112 patients, 75%). A history of dentoalveolar 
surgery was inversely associated (hazard ratio, HR = 0.71, 95%CI 0.56 to 0.91) and the use of 
antiangiogenics (HR = 1.10, 95%CI 1.01 to 1.19) directly associated with TTO in the subgroup of 
cancer patients taking ZOL (Model 1).  
 
DISCUSSION 
Cumulative dosage and duration of anti-resorptive therapy are two of the most consistently 
reported risk factors for ONJ development (Thumbigere-Math et al, 2012; Fleisher et al, 2013) 
and there remains little doubt that ONJ is a time- and dose-related adverse effect. However, data 
regarding TTO are controversial as they vary significantly among studies (Palaska et al, 2009). 
Fleisher et al. (Fleisher et al, 2013) reported a median time of 3 and 5 years for ONJ to develop 
in individuals using intravenous and oral BP respectively, whereas a 2009 review reported a 
mean time of 1.8 and 4.6 years after ZOL and ALE therapy, respectively (Palaska et al, 2009). 
Other authors reported that ONJ developed after only 4 months of ZOL therapy, which they 
suggest was possibly triggered by invasive dental surgical procedures (Saussez et al, 2009). 
Moreover, a recent study of 191 ONJ cases recruited in a primary care setting (dental practice-
based research network) reported a 10-fold increase in risk of ONJ associated with <2 years of 
BP therapy, which increased to 40-fold among individuals treated with BP for more than 2 years 
(Barasch et al, 2011). 
 
Such inconsistency in the data on TTO has negative clinical consequences as it can hinder the 
delivery of potential risk-reduction strategies such as prophylactic dental measures and BP 
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dosage reduction or discontinuation. It can also affect the delivery of clinical surveillance 
programs (Kyle et al, 2007; Kyrgidis et al, 2013) and cause confusion in the interpretation of 
clinical studies. For example, clinical trials with a short observation time, e.g. shorter than the 
median TTO, would miss a significant number of incident cases and therefore provide flawed 
estimates of ONJ incidence and its risk factors. The most likely reasons accounting for the 
inconsistency and variability of current TTO estimates are different study designs, generally low 
sample sizes, ambiguous definitions of TTO, short follow-up times, and diagnostic criteria 
limited to exposed ONJ (Palaska et al, 2009). The present study was undertaken with the aim of 
overcoming these limitations. A significant strength of our study is the large sample size (n = 
349), making it the largest study performed so far to investigate TTO.  Another strength of our 
study is the use of a strict definition of TTO as the time elapsed between the commencement of 
BP therapy and ONJ diagnosis, as determined by a multidisciplinary team. Previous studies have 
interchangeably used TTO as per clinicians’ diagnosis and TTO as based on symptoms reported 
by patients (Bamias et al, 2005; Pozzi et al, 2007; Mavrokokki et al, 2007; Boonyapakorn et al, 
2008; Vahtsevanos et al, 2009; Saia et al, 2010; Hasegawa et al, 2012; Watters et al, 2013) and 
other studies have used unclear diagnostic criteria (Palaska et al, 2009). On the contrary, our 
study defined TTO precisely and consistently among centres and avoided the bias associated 
with the mixing of the diagnoses made by physicians and those made by patients (Lazarovici et 
al, 2009). The use of strict diagnostic criteria in multicentre cross-sectional cohort studies 
reduces the risk of selection bias (Hudson et al, 2005).  
 
We estimated a median TTO of 3.2 years in the whole cohort. When stratified by BP type, the 
median TTO was 6.0 years for ALE and 2.2 for ZOL. The corresponding figures were 2.1 years 
for IBA, 2.4 years for RIS and 6.2 years for PAM. With respect to the cumulative incidence 
(numbers and percentages) of individuals being diagnosed with ONJ at different time points 
after commencement of BP therapy (Figure 1), our analysis shows that it took 4.1 years for 75% 
of ZOL-exposed ONJ patients and 8.5 years for 75% of ALE-exposed ONJ patients to develop 
their disease. Also, 50% of ZOL-exposed and ALE-exposed ONJ individuals developed their 
disease in 2.2 and 6 years. 
 
Our results are not notably different from those of previous studies, which were mostly single-
centre and had much smaller cohorts. The three largest single-centre studies performed so far 
include the 60 ZOL ONJ cases reported by Watters et al. (Marx et al, 2007; Watters et al, 2013), 
the 27 ALE ONJ cases described by Marx et al. (Marx et al, 2007; Watters et al, 2013), and the 31 
ZOL- and 16 ALE-related ONJ cases reported by Lazarovici et al. (Lazarovici et al, 2009), which 
grouped together make up a smaller sample than the one we recruited and studied. These 
studies reported a median time to onset of 1.75 years for ZOL-related ONJ (Marx et al, 2007; 
Watters et al, 2013), 5.7 years for ALE-related ONJ (Marx et al, 2007; Watters et al, 2013), and 
median times of 2 and 5 years the ZOL-related and ALE-related ONJ, respectively (Lazarovici et 
al, 2009). Our study confirms that ZOL is associated with a shorter TTO with respect to ALE 
(Bamias et al, 2005; Pozzi et al, 2007; Mavrokokki et al, 2007; Boonyapakorn et al, 2008; 
Vahtsevanos et al, 2009; Thumbigere-Math et al, 2012; Watters et al, 2013), which is consistent 
with the greater potency and better bioavailability of intravenous ZOL. However, in the present 
study, the median TTO was slightly longer than in previous studies for both ZOL and ALE. 
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Another strength of this study is the use of multivariable analysis to investigate the joint 
association of potential risk factors with TTO. Previous studies suggested that a number of risk 
factors may have an “additive” impact on ONJ pathogenesis, therefore leading to shorter TTO 
(Bamias et al, 2005; Pozzi et al, 2007; Mavrokokki et al, 2007; Thumbigere-Math et al, 2012; 
Boonyapakorn et al, 2008; Palaska et al, 2009; Vahtsevanos et al, 2009; Saia et al, 2010; 
Hasegawa et al, 2012; Fleisher et al, 2013; Watters et al, 2013). These factors included 
corticosteroid use, smoking, alcohol, T2DM, dental extraction and use of dentures (Bamias et al, 
2005; Pozzi et al, 2007; Mavrokokki et al, 2007; Boonyapakorn et al, 2008; Palaska et al, 2009; 
Vahtsevanos et al, 2009; Saia et al, 2010; Hasegawa et al, 2012; Watters et al, 2013). Our study 
considered up to 7 risk factors in a multivariable regression model (Harrell et al, 1996) and 
shows that none of the previously suggested variables is associated with shorter TTO, including 
dental risk factors (alveolar surgery and use of dentures). In the subgroup of cancer patients 
taking ZOL, the only factor associated with shorter TTO in the present study was the use of anti-
angiogenic agents (Table 2). This was not unexpected, as antiangiogenic medications are known 
to cause ONJ per se. Quite surprisingly, a history of dento-alveolar surgery to the jawbones was 
associated with a lower hazard for ONJ in the same subgroup of cancer patients taking ZOL. It is 
not clear why ONJ developed faster in individuals who had not received dento-alveolar surgery. 
Of note, despite the relatively large number of subjects compared to the predictors (7 for Model 
1 and 6 for Model 2), the estimated hazard ratios have wide 95%CI suggesting that larger 
samples are needed to estimate these effects more precisely. 
 
 
A limitation of the present study lies in its retrospective nature. However, provided that the 
outcome can be thoroughly assessed, retrospective cohort designs offer a number of advantages 
over prospective cohort designs if the time to outcome is long (Hudson et al, 2005). For 
example, based on the present study, one can estimate that a hypothetical prospective study 
observing cancer patients for 2 years after the start of ZOL therapy would identify less than 
50% of incident ONJ cases. This would not only decrease the confidence with such incidence 
estimate can be accepted, but also may identify different risk factors from those identifiable 
with a longer follow-up. 
 
Conclusions 
This is the largest study performed to date to investigate TTO and its risk factors. It has been 
conducted in a large well-phenotyped multicentre cohort, with a strict definition of the 
outcomes, clear diagnostic criteria, and the use of multivariable regression modelling. We 
believe that its findings can be promptly translated into clinical application to inform the design 
of clinical trials, epidemiological studies and surveillance programs. For example, a follow-up of 
at least 2.2 and 6.0 years is needed to capture at least 50% of the incident cases of ONJ in ZOL 
and ALE users respectively. Corresponding figures of 4.1 and 8.5 years are needed to capture 
instead 75% of ZOL-exposed and ALE-exposed ONJ incident cases. Clinicians should expect that 
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ZOL-treated cancer patients who also receive anti-angiogenic therapy may develop ONJ earlier 
than other patients.  
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Tables and figures 
 
Table 1: Details of the study cohort and time to event stratified by potential risk factors.  
 
Potential risk factor N % Median Time to event (years) 
(95%CI) 
 
Age (decade) 
 
30-39 
40-49 
50-59 
60-69 
70-79 
80-89 
Total 
2 
8 
41 
125 
134 
39 
349 
0.6 
2.3 
11.7 
35.8 
38.4 
11.2 
100 
2.2 (2.2 to NA) 
3.7 (0.4 to 7.5) 
2.4 (1.6 to 3.5) 
3.3 (2.8 to 4.3) 
2.8 (2.2 to 3.7) 
4.2 (2.9 to 5.8) 
3.2 (2.8 to 3.7) 
Gender Female 
Male 
247 
102 
70.8 
29.2 
3.9 (3.2 to 4.3) 
2.1 (1.8 to 2.6) 
Race Caucasian 
Other 
323 
26 
92.6 
7.4 
3.2 (2.8 to 3.7) 
2.9 (2.4 to 5.4) 
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Underlying disease Metastatic Breast Cancer (MBC) 
Multiple Myeloma (MM) 
Metastatic Prostate Cancer (MPC) 
Other Cancers (OC) 
Osteoporosis (OP) 
84 
93 
33 
27 
112 
24.1 
26.6 
9.5 
7.7 
32.1 
3.1 (2.2 to 3.6) 
2.3 (2.1 to 3.0) 
1.8 (1.6 to 2.1) 
2.1 (1.0 to 2.8) 
5.3 (4.4 to 6.1)  
BP type Alendronate (ALE) 
Ibandronate (IBA) 
Pamidronate (PAM) 
Risedronate (RIS) 
Zoledronate (ZOL) 
88 
15 
17 
11 
218 
25.2 
4.3 
4.9 
3.2 
62.5 
6.0 (5.3 to 6.4) 
2.1 (0.6 to 3.2) 
6.2 (4.6 to 7.2) 
2.4 (0.3 to 4.7) 
2.2 (2.1 to 2.6) 
Medical History Corticosteroids 
Antiangiogenics* 
Type 2 diabetes mellitus 
Smoking 
76 
49 
34 
74 
21.8 
14.0 
9.7 
21.1 
3.2 (2.6 to 4.1) 
2.3 (1.8 to 3.2) 
2.9 (2.3 to 4.6) 
3.4 (2.6 to 4.5) 
Dental History Dento-alveolar surgery 
Denture use 
186 
73 
53.3 
20.9 
3.9 (3.2 to 4.5) 
4.2 (2.7 to 5.3) 
ONJ features Non-exposed type 
Exposed type 
Maxilla 
Mandible 
Both maxilla and mandible 
31 
318 
88 
227 
34 
8.9 
91.1 
25.2 
65.0 
9.7 
3.3 (1.7 to 5.8) 
3.2 (2.8 to 3.7) 
3.3 (2.7 to 3.9) 
2.9 (2.4 to 3.6) 
4.2 (3.0 to 5.1) 
 
N = number of patients;  NA = not available;  * bevacizumab, sunitinib, thalidomide, lenalidomide, bortezomib 
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Table 2:  Multivariable Cox regression of factors potentially associated with TTO of ONJ in 
cancer patients taking ZOL (Model 1) and in non-cancer patients taking ALE (Model 2). 
Cluster confidence intervals were calculated using the study country as cluster. 
 
 
 MODEL 1 MODEL 2 
 Cancer patients 
taking ZOL 
Non-cancer patients 
taking ALE 
   
Male sex (1= yes; 0 =no) 1.25 [0.92, 1.68] 1.12 [0.50, 2.53] 
   
Age/10 (years) 0.97 [0.92, 1.03] 1.06 [0.83, 1.34] 
   
Dentoalveolar surgery (1= yes; 0 =no) 0.71 ** [0.92, 1.03] 1.03 [0.68, 1.23] 
   
Type 2 Diabetes Mellitus (1= yes; 0 =no) 1.00 [0.92, 1.09] 0.94 [0.59, 1.51] 
   
Smoking (1= yes; 0 =no) 1.00 [0.74, 1.36] 1.05 [0.70, 1.58] 
   
Corticosteroids (1= yes; 0 =no) 1.18 [0.92, 1.50] 1.06 [0.90, 1.25] 
   
Antiangiogenics (1= yes; 0 =no) 1.10 * [1.01, 1.19] -- 
   
N 212 84 
 
Values of hazard rates from multivariable Cox regression with 95% confidence intervals in 
brackets  
* p <0.05,  ** p <0.01 
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Figure Captions 
Figure 1: Kaplan-Meier curves of number and percentage of patients developing ONJ over time. 
The data are obtained from a retrospective cohort study including only patients who developed 
ONJ (see text for details). Stratification by [A] underlying disease (cancer vs. non-cancer), [B] 
bisphosphonate type, and [C] underlying disease (all). MBC: metastatic breast cancer; MPC: 
metastatic prostate cancer; MM: multiple myeloma; OC: other cancers; OP: osteoporosis; ALE: 
alendronate; PAM: pamidronate, ZOL: zoledronate; IBA: ibandronate; RIS: risedronate.  
 
 
 
